NIKKEI 225
27,522.26 -250.64 (-0.90%) HANG SENG
24,965.55 +13.25 (+0.05%) CRUDE OIL
undefined (0) GOLD FUTURES
1,841.10 -0.60 (-0.03%) DOW
34,364.50 +99.10 (+0.29%) BTC-GBP
26,940.28 +641.96 (+2.44%)
DBV Technologies S.A. (DBVT)
After hours:
| Previous close | 1.5700 |
| Open | 1.4800 |
| Bid | 1.5400 x 800 |
| Ask | 1.6300 x 1000 |
| Day's range | 1.3750 - 1.4800 |
| 52-week range | 1.3510 - 6.8800 |
| Volume | |
| Avg. volume | 706,162 |
| Market cap | 166.089M |
| Beta (5Y monthly) | 2.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1260 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.99 |
- Globe Newswire
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF REGULATED INFORMATIONMontrouge, France, January 21, 2022 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. As of December 31, 2021, the following assets appeared on the liquidity account: 153,631 DBV Technologies shares;€ 175,542.33. Upon signing the liquidity contract
- Globe Newswire
Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021
Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights12/31/202155,095,762 Total gross of voting rights: 55,095,762 Total net* of voting rights: 54,942,131 * Total net = total number of voting rights attached to shares – shares wi
- Globe Newswire
DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference
Montrouge, France, January 7, 2022 DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference. The fireside chat will be available for on-demand viewing starting Monday, January 10, 2022, at 7:00am ET. A webc
